Commercializing BiomarkersTherapeutic and Diagnostic Market
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Consumables
1.2.3 Services
1.2.4 Software
1.3 Market by Application
1.3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Perspective (2016-2027)
2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Growth Trends by Regions
2.2.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Share by Regions (2016-2021)
2.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Regions (2022-2027)
2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Dynamic
2.3.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Trends
2.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers
2.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
2.3.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue
3.1.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue (2016-2021)
3.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Players (2016-2021)
3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue
3.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio
3.4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2020
3.5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Key Players Head office and Area Served
3.6 Key Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Solution and Service
3.7 Date of Enter into Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Type
4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Type (2016-2021)
4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (2022-2027)
5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Application
5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Application (2016-2021)
5.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2016-2027)
6.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
6.2.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021)
6.2.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2022-2027)
6.2.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2027)
6.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
6.3.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2021)
6.3.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2022-2027)
6.3.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2027)
6.4 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
6.4.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2016-2021)
6.4.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2016-2027)
7.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
7.2.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021)
7.2.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2022-2027)
7.2.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2027)
7.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
7.3.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2021)
7.3.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2022-2027)
7.3.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2027)
7.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
7.4.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2016-2021)
7.4.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2016-2027)
8.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
8.2.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2027)
8.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
8.3.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2027)
8.4 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region
8.4.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2016-2027)
9.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
9.2.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021)
9.2.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2022-2027)
9.2.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2027)
9.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
9.3.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2021)
9.3.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2022-2027)
9.3.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2027)
9.4 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
9.4.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2016-2021)
9.4.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2016-2027)
10.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
10.2.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2027)
10.3 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
10.3.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2027)
10.4 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
10.4.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.1.4 Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Dako (Agilent Technologies)
11.2.1 Dako (Agilent Technologies) Company Details
11.2.2 Dako (Agilent Technologies) Business Overview
11.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.2.4 Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.2.5 Dako (Agilent Technologies) Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.3.4 Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.3.5 Merck Recent Development
11.4 BD
11.4.1 BD Company Details
11.4.2 BD Business Overview
11.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.4.4 BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.4.5 BD Recent Development
11.5 Abbott
11.5.1 Abbott Company Details
11.5.2 Abbott Business Overview
11.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.5.4 Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.5.5 Abbott Recent Development
11.6 Genesys Biolabs (20/20GeneSystems)
11.6.1 Genesys Biolabs (20/20GeneSystems) Company Details
11.6.2 Genesys Biolabs (20/20GeneSystems) Business Overview
11.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.6.4 Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.6.5 Genesys Biolabs (20/20GeneSystems) Recent Development
11.7 Affymetrix
11.7.1 Affymetrix Company Details
11.7.2 Affymetrix Business Overview
11.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.7.4 Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.7.5 Affymetrix Recent Development
11.8 Agendia
11.8.1 Agendia Company Details
11.8.2 Agendia Business Overview
11.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.8.4 Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.8.5 Agendia Recent Development
11.9 ALMAC
11.9.1 ALMAC Company Details
11.9.2 ALMAC Business Overview
11.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.9.4 ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.9.5 ALMAC Recent Development
11.10 Arrayit
11.10.1 Arrayit Company Details
11.10.2 Arrayit Business Overview
11.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.10.4 Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.10.5 Arrayit Recent Development
11.11 Biocartic
11.11.1 Biocartic Company Details
11.11.2 Biocartic Business Overview
11.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.11.4 Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.11.5 Biocartic Recent Development
11.12 BG Medicine
11.12.1 BG Medicine Company Details
11.12.2 BG Medicine Business Overview
11.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.12.4 BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.12.5 BG Medicine Recent Development
11.13 KEGG EXPRESSION Database
11.13.1 KEGG EXPRESSION Database Company Details
11.13.2 KEGG EXPRESSION Database Business Overview
11.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.13.4 KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.13.5 KEGG EXPRESSION Database Recent Development
11.14 Thermo Fisher
11.14.1 Thermo Fisher Company Details
11.14.2 Thermo Fisher Business Overview
11.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.14.4 Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.14.5 Thermo Fisher Recent Development
11.15 BGI
11.15.1 BGI Company Details
11.15.2 BGI Business Overview
11.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.15.4 BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
11.15.5 BGI Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Consumables
Table 3. Key Players of Services
Table 4. Key Players of Software
Table 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Regions (2016-2021)
Table 9. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Regions (2022-2027)
Table 11. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Trends
Table 12. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers
Table 13. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
Table 14. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
Table 15. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Players (2016-2021)
Table 17. Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications as of 2020)
Table 18. Ranking of Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Solution and Service
Table 22. Date of Enter into Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Type (2016-2021)
Table 26. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Application (2016-2021)
Table 30. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2022-2027) & (US$ Million)
Table 62. Roche Company Details
Table 63. Roche Business Overview
Table 64. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 65. Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 66. Roche Recent Development
Table 67. Dako (Agilent Technologies) Company Details
Table 68. Dako (Agilent Technologies) Business Overview
Table 69. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 70. Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 71. Dako (Agilent Technologies) Recent Development
Table 72. Merck Company Details
Table 73. Merck Business Overview
Table 74. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 75. Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 76. Merck Recent Development
Table 77. BD Company Details
Table 78. BD Business Overview
Table 79. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 80. BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 81. BD Recent Development
Table 82. Abbott Company Details
Table 83. Abbott Business Overview
Table 84. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 85. Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 86. Abbott Recent Development
Table 87. Genesys Biolabs (20/20GeneSystems) Company Details
Table 88. Genesys Biolabs (20/20GeneSystems) Business Overview
Table 89. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 90. Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 91. Genesys Biolabs (20/20GeneSystems) Recent Development
Table 92. Affymetrix Company Details
Table 93. Affymetrix Business Overview
Table 94. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 95. Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 96. Affymetrix Recent Development
Table 97. Agendia Company Details
Table 98. Agendia Business Overview
Table 99. Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 100. Agendia Recent Development
Table 101. ALMAC Company Details
Table 102. ALMAC Business Overview
Table 103. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 104. ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 105. ALMAC Recent Development
Table 106. Arrayit Company Details
Table 107. Arrayit Business Overview
Table 108. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 109. Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 110. Arrayit Recent Development
Table 111. Biocartic Company Details
Table 112. Biocartic Business Overview
Table 113. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 114. Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 115. Biocartic Recent Development
Table 116. BG Medicine Company Details
Table 117. BG Medicine Business Overview
Table 118. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 119. BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 120. BG Medicine Recent Development
Table 121. KEGG EXPRESSION Database Company Details
Table 122. KEGG EXPRESSION Database Business Overview
Table 123. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 124. KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 125. KEGG EXPRESSION Database Recent Development
Table 126. Thermo Fisher Company Details
Table 127. Thermo Fisher Business Overview
Table 128. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 129. Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 130. Thermo Fisher Recent Development
Table 131. BGI Company Details
Table 132. BGI Business Overview
Table 133. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 134. BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021) & (US$ Million)
Table 135. BGI Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type: 2020 VS 2027
Figure 2. Consumables Features
Figure 3. Services Features
Figure 4. Software Features
Figure 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application: 2020 VS 2027
Figure 6. Oncology Case Studies
Figure 7. Cardiology Case Studies
Figure 8. Neurology Case Studies
Figure 9. Other Case Studies
Figure 10. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Report Years Considered
Figure 11. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Regions: 2020 VS 2027
Figure 14. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Regions (2022-2027)
Figure 15. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Players in 2020
Figure 16. Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2020
Figure 18. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Type (2016-2021)
Figure 19. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Type (2022-2027)
Figure 20. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2016-2027)
Figure 22. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2016-2027)
Figure 23. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2016-2027)
Figure 24. United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2016-2027)
Figure 28. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2016-2027)
Figure 29. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2016-2027)
Figure 30. Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region (2016-2027)
Figure 40. China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2016-2027)
Figure 48. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2016-2027)
Figure 49. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2016-2027)
Figure 50. Mexico Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Country (2016-2027)
Figure 56. Turkey Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Roche Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 60. Dako (Agilent Technologies) Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 61. Merck Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 62. BD Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 63. Abbott Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 64. Genesys Biolabs (20/20GeneSystems) Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 65. Affymetrix Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 66. Agendia Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 67. ALMAC Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 68. Arrayit Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 69. Biocartic Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 70. BG Medicine Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 71. KEGG EXPRESSION Database Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 72. Thermo Fisher Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 73. BGI Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
